Molecular imaging agent developer On Target Laboratories is highlighting the results of a study showing the effectiveness of its Cytalux (pafolacianine) agent in intraoperative imaging of folate receptor-positive ovarian cancer.
In a study published September 7 in the Journal of Clinical Oncology, researchers reported data from 150 patients who received a single infusion of Cytalux during ovarian cancer surgery.
They found that in 33% of the 109 patients with folate receptor-positive ovarian cancer, near-infrared imaging with Cytalux identified additional lesions that would have been left behind (p < 0.001).
Furthermore, the researchers found that the rate of additional lesion detection was higher, at 39.7%, among patients who underwent interval debulking surgery, Cytalux said.
